An update on primary sclerosing cholangitis

Current Opinion in Gastroenterology

Volumn 24, Issue 3, 2008, Pages 377-383

  Maggs, James R L ^a   Chapman, Roger W ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Autoimmune pancreatitis; Cholangiocarcinoma; Orthotopic liver transplantation; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HLA ANTIGEN; SILYMARIN; TACROLIMUS; URSODEOXYCHOLIC ACID;

ADAPTIVE IMMUNITY; AUTOIMMUNE PANCREATITIS; BACTERIUM; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILIARY DUCT DYSPLASIA; BILIARY TRACT DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DEPRESSION; DNA POLYMORPHISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; ENTERITIS; EPITHELIUM CELL; ESOPHAGUS VARICES; GALLBLADDER CARCINOMA; GALLBLADDER DISEASE; GALLBLADDER MALFORMATION; GALLBLADDER POLYP; HAPLOTYPE; HELICOBACTER; HUMAN; INNATE IMMUNITY; LIVER; LIVER DISEASE; LIVER TRANSPLANTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MUTATION; POLYMORPHISM, GENETIC;

EID: 42149161075     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282f9e239     Document Type: Review

References (41)

1. Karlsen TH, Schrumpf E, Boberg KM. Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol 2007; 13:5421-5431. A detailed review summarizing the present knowledge on the genetic associations with disease susceptibility, disease progression and clinical subsets.
2. Wiencke K, Karlsen TH, Boberg KM, et al. Primary sclerosing cholangitis is associated with extended HLA-DR3 and HLA-DR6 haplotypes. Tissue Antigens 2007; 69:161-169.
3. Karlsen TH, Boberg KM, Olsson M, et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 2007; 46:899-906.
4. Henckaerts L, Fevery J, Van Steenbergen W, et al. The RANTES -28G polymorphism is associated with primary sclerosing cholangitis. Gut 2007; 56:891-892.
5. Karlsen TH, Hampe J, Wiencke K, et al. Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol 2007; 102:115-121.
6. Karlsen TH, Boberg KM, Vatn M, et al. Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun 2007; 8:275-278.
7. Elias E, Mills CO. Coordinated defence and the liver. Clin Med 2007; 7:180-184. An excellent review of the metabolism of toxic bile acids, focusing on how dysfunction of these mechanisms may play a role in the pathogenesis of PSC.
8. Preuss B, Berg C, Altenberend F, et al. Demonstration of autoantibodies to recombinant human sulphite oxidase in patients with chronic liver disorders and analysis of their clinical relevance. Clin Exp Immunol 2007; 150:312-321.
9. Karrar A, Broome U, Sodergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007; 132:1504-1514. This study demonstrates that in PSC biliary epithelial cells may play a role in their own destruction, as the result of exaggerated immune responses.
10. Sheth P, Delos Santos N, Seth A, et al. Lipopolysaccharide disrupts tight junctions in cholangiocyte monolayers by a c-Src-, TLR4-, and LBP-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2007; 293:G308-G318. This study highlights the potential role of lipopolysaccharide in disrupting the barrier function of an animal model of the biliary epithelium.
11. Krasinskas AM, Yao Y, Randhawa P, et al. Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig Dis Sci 2007; 52:2265-2270.
12. Henkel C, Roderfeld M, Weiskirchen R, et al. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. Proteomics 2006; 6:6538-6548.
13. Fickert P, Stoger U, Fuchsbichler A, et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol 2007; 171:525-536.
14. Fickert P, Moustafa T, Trauner M. Primary sclerosing cholangitis: the arteriosclerosis of the bile duct? Lipids Health Dis 2007; 6:3. An interesting hypothesis is proposed, suggesting that PSC is 'atherosclerosis of the bile duct'.
15. Bergquist A, Said K, Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol 2007; 42:88-93. This study documents the changes in the clinical presentation of PSC in the last two decades in Sweden, focusing on the impact of noninvasive diagnostic methods.
16. Tischendorf JJ, Hecker H, Kruger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007; 102:107-114.
17. Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007; 102:1042-1049. This Canadian population-based study reports the epidemiology of small duct PSC in adults and children.
18. Charatcharoenwitthaya P, Angulo P, Enders FB, et al. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology 2007; 47:133-142.
19. van Os E, van den Broek WW, Mulder PG, et al. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2007; 46:1099-1103.
20. Bjornsson E, Chari ST, Smyrk TC, et al. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007; 45:1547-1554. A review of the literature published on AIP, in which the authors suggest an alternative term for this recently recognized clinical entity.
21. Fevery J, Verslype C, Lai G, et al. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007; 52:3123-3135. A comprehensive review of the management of PSC patients with cholangiocarcinoma.
22. Moreno Luna LE, Gores GJ. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl 2006; 12:S15-S19.
23. Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am J Gastroenterol 2007; 102:1677-1682.
24. Tischendorf JJ, Meier PN, Strassburg CP, et al. Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2006; 41:1227-1234.
25. Lempinen M, Isoniemi H, Makisalo H, et al. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol 2007; 47:677-683.
26. DeHaan RD, Kipp BR, Smyrk TC, et al. An assessment of chromosomal alterations detected by fluorescence in situ hybridization and p16 expression in sporadic and primary sclerosing cholangitis-associated cholangiocarcinomas. Hum Pathol 2007; 38:491-499.
27. Tischendorf JJ, Meier PN, Schneider A, et al. Transpapillary intraductal ultrasound in the evaluation of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2007; 42:1011-1017.
28. Prytz H, Keiding S, Bjornsson E, et al. Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology 2006; 44:1572-1580.
29. Lewis JT, Talwalkar JA, Rosen CB, et al. Prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for a metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol 2007; 31:907-913.
30. Leung UC, Wong PY, Roberts RH, et al. Gall bladder polyps in sclerosing cholangitis: does the 1-cm rule apply? ANZ J Surg 2007; 77:355-357.
31. Nyblom H, Nordlinder H, Olsson R. High aspartate to alanine aminotransferase ratio is an indicator of cirrhosis and poor outcome in patients with primary sclerosing cholangitis. Liver Int 2007; 27:694-699.
32. Meagher S, Yusoff I, Kennedy W, et al. The roles of magnetic resonance and endoscopic retrograde cholangiopancreatography (MRCP and ERCP) in the diagnosis of patients with suspected sclerosing cholangitis: a cost-effectiveness analysis. Endoscopy 2007; 39:222-228.
33. Petrovic BD, Nikolaidis P, Hammond NA, et al. Correlation between findings on MRCP and gadolinium-enhanced MR of the liver and a survival model for primary sclerosing cholangitis. Dig Dis Sci 2007; 52:3499-3506.
34. Vacca M, Krawczyk M, Petruzzelli M, et al. Current treatments of primary sclerosing cholangitis. Curr Med Chem 2007; 14:2081-2094.
35. Rost D, Kulaksiz H, Stiehl A. Treatment of primary sclerosing cholangitis. Curr Treat Options Gastroenterol 2007; 10:111-119.
36. Smith T, Befeler AS. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Curr Gastroenterol Rep 2007; 9:54-59.
37. Rudolph G, Kloeters-Plachky P, Rost D, et al. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007; 19:487-491.
38. Talwalkar JA, Gossard AA, Keach JC, et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int 2007; 27:451-453. This pilot study investigates the potential role of tacrolimus in the treatment of PSC.
39. Angulo P, Jorgensen RA, Kowdley KV, et al. Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig Dis Sci 2007; 17 October [Epub ahead of print]. This pilot study evaluates the efficacy and safety of silymarin, the active ingredient of milkthistle, in the treatment of PSC.
40. Gordon F. Recurrent primary sclerosing cholangitis: clinical diagnosis and long-term management issues. Liver Transpl 2006; 12:S73-S75.
41. Tamura S, Sugawara Y, Kaneko J, et al. Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int 2007; 27:86-94.